Evaluation of Immune Response to Measles Component of MMR Vaccine in Children with HIV Infection Receiving Antiretroviral Therapy
Authors:
- 1 January 2016
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 35 (1) , e8-e11
Abstract
Background: Children with HIV (CLHIV) respond poorly to primary immunization with measles vaccine and those responding tend to lose protective titer of antibodies by 2–3 years old. Revaccinating CLHIV after immune reconstitution with antiretroviral therapy (ART) may result in good seroconversion, thereby conferring them protection from measles. The objective was to study prevalence of measles antibodies in CLHIV receiving ART before and after immunization with MMR vaccine. Methods: CLHIV in the age 5–18 years receiving ART for >6 months and with CD 4 count >15% were included in this prospective study. Their serum was assayed for IgG measles antibodies by qualitative immune-enzymatic determination using enzyme linked immunosorbent assay. The subjects were then immunized with a single dose of MMR vaccine. A repeat venous sample was assayed for measles antibodies 8–12 weeks after immunization. Results: Sixty-six subjects (46 males, 20 females, mean age 10.4 ± 2.8 years) were enrolled. The mean duration of ART was 3.4 ± 1.5 years and median CD4 count 716.5 μ/L (interquartile range: 563.3–950). At enrollment, 16 (24.2%) subjects tested positive, 8 (12.1%) equivocal and 42 (63.6%) negative for measles antibodies. After 8–12 weeks of immunization, 62 (93.3%) tested positive, 1 (1.5%) equivocal, and 3 (4.5%) negative. There was no difference among the seropositive and seronegative subjects postimmunization with respect to age, sex, duration of ART, nutritional status, CD4 count, or WHO clinical stage. No serious adverse reaction was observed to vaccination. Conclusions: MMR vaccine leads to an excellent seroconversion to measles component of vaccine in immune-reconstituted CLHIV.Keywords
This publication has 16 references indexed in Scilit:
- Measles Seropositivity in HIV-infected Kenyan Children on Antiretroviral TherapyThe Pediatric Infectious Disease Journal, 2014
- Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and RevaccinationThe Pediatric Infectious Disease Journal, 2009
- HIV Type 1 Infection Is a Risk Factor for Mortality in Hospitalized Zambian Children with MeaslesClinical Infectious Diseases, 2008
- The Influence of HIV-1 Exposure and Infection on Levels of Passively Acquired Antibodies to Measles Virus in Zambian InfantsClinical Infectious Diseases, 2007
- Immunogenicity of Standard‐Titer Measles Vaccine in HIV‐1–Infected and Uninfected Zambian Children: An Observational StudyThe Journal of Infectious Diseases, 2007
- Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapyHIV Medicine, 2006
- Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy–Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral InfectionPediatrics, 2006
- Prospective Study of Measles in Hospitalized, Human Immunodeficiency Virus (HIV)–Infected and HIV–Uninfected Children in ZambiaClinical Infectious Diseases, 2002
- Prolonged Measles Virus Shedding in Human Immunodeficiency Virus–Infected Children, Detected by Reverse Transcriptase–Polymerase Chain ReactionThe Journal of Infectious Diseases, 2001
- Increased Risk of Early Measles in Infants of Human Immunodeficiency Virus Type 1-Seropositive MothersThe Journal of Infectious Diseases, 1992